Aurobindo Pharma Ltd

NSE: AUROPHARMA · BSE: 524804 · Pharmaceuticals & Biotechnology · 10 announcements

Share price: ₹1,712.00
Market cap: ₹99,433 Cr
Revenue (annual): ₹33,653 Cr
Net profit (annual): ₹3,505 Cr
P/E (TTM): 25.2×Sector 50.4×
Promoter holding: 51.88%+0.06% QoQ
FII holding: 16.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 2 Regulatory Approval 1 Merger & Restructuring 1 Financial Results 1 Business Update 1 Acquisition 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

13 Aug 2026 17:59 IST BSE

Earnings Call

Aurobindo Pharma Earnings Call Transcript: Key Takeaways

Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.

Call: Guides 10% growth

Open call summary → Read the filing ↗

5 Aug 2026 19:55 IST BSE

Earnings Call

Aurobindo Pharma Investor Presentation: Key Takeaways

Aurobindo reported strong Q1FY27 performance with revenue up 16.3% YoY to ₹9,150 Cr and PAT up 25.2% to ₹1,032 Cr, driven by US base business volume gains and European expansion.

Open call summary → Read the filing ↗